Statement: All cancer stages are accepted for the primary trial and the secondary trial.
Primary_evidence: Inclusion Criteria:   New diagnosis of breast cancer   New diagnosis if a previous breast cancer patient with negative surgical margins   Patients willing to sign a written informed consent form Exclusion Criteria:   High risk benign lesions as the primary pathology diagnosis
Secondary_evidence: Inclusion Criteria:   History of ductal carcinoma in situ, lobular carcinoma in situ or stages 1-3 breast cancer   Not currently receiving chemotherapy or hormonal therapy   Postmenopausal Exclusion Criteria:   Stage IV breast cancer or systemic recurrences   Prior malignancies of any type other than breast cancer, basal or squamous cell carcinoma of the skin or carcinoma in situ of the cervix   Use of adjuvant hormonal therapy, oral estrogen or progesterone replacement therapy, lutenizing hormone releasing hormone agonists currently or within the past 60 days   Concomitant use of beta-blockers   Concomitant nightly use of sleep aids at bedtime   Working more than one overnight shift per month on a regular basis   Concomitant use of postmenopausal hormone replacement therapy   Concomitant use of black cohosh, flaxseed or soy in pill or supplement form   Use of any type of oral melatonin supplementation within the past 30 days   Use of warfarin (coumadin) within the past 30 days   Active seizure disorder requiring the use of daily anti-epileptic medication